164 related articles for article (PubMed ID: 32667731)
61. A combination of STI571 and BCR-ABL1 siRNA with overexpressed p15INK4B induced enhanced proliferation inhibition and apoptosis in chronic myeloid leukemia.
Xia DY; Liu L; Hao MW; Liu Q; Chen RA; Liang YM
Braz J Med Biol Res; 2014 Dec; 47(12):1096-101. PubMed ID: 25387678
[TBL] [Abstract][Full Text] [Related]
62. RITA induces apoptosis in p53-null K562 leukemia cells by inhibiting STAT5, Akt, and NF-κB signaling pathways.
Mobaraki RN; Karimi M; Alikarami F; Farhadi E; Amini A; Bashash D; Paridar M; Kokhaei P; Rezvani MR; Kazemi A; Safa M
Anticancer Drugs; 2018 Oct; 29(9):847-853. PubMed ID: 30157040
[TBL] [Abstract][Full Text] [Related]
63. Novel AF1q/MLLT11 favorably affects imatinib resistance and cell survival in chronic myeloid leukemia.
Li W; Ji M; Lu F; Pang Y; Dong X; Zhang J; Li P; Ye J; Zang S; Ma D; Ji C
Cell Death Dis; 2018 Aug; 9(9):855. PubMed ID: 30154435
[TBL] [Abstract][Full Text] [Related]
64. Inhibitors Targeting STAT5 Signaling in Myeloid Leukemias: New Tetrahydroquinoline Derivatives with Improved Antileukemic Potential.
Polomski M; Brachet-Botineau M; Juen L; Viaud-Massuard MC; Gouilleux F; Prié G
ChemMedChem; 2021 Mar; 16(6):1034-1046. PubMed ID: 33275308
[TBL] [Abstract][Full Text] [Related]
65. Divalproex sodium enhances the anti-leukemic effects of imatinib in chronic myeloid leukemia cells partly through SIRT1.
Wang W; Zhang J; Li Y; Yang X; He Y; Li T; Ren F; Zhang J; Lin R
Cancer Lett; 2015 Jan; 356(2 Pt B):791-9. PubMed ID: 25449787
[TBL] [Abstract][Full Text] [Related]
66. Erosion of the chronic myeloid leukaemia stem cell pool by PPARγ agonists.
Prost S; Relouzat F; Spentchian M; Ouzegdouh Y; Saliba J; Massonnet G; Beressi JP; Verhoeyen E; Raggueneau V; Maneglier B; Castaigne S; Chomienne C; Chrétien S; Rousselot P; Leboulch P
Nature; 2015 Sep; 525(7569):380-3. PubMed ID: 26331539
[TBL] [Abstract][Full Text] [Related]
67. Preclinical development of a novel BCR-ABL T315I inhibitor against chronic myeloid leukemia.
Gupta P; Zhang GN; Barbuti AM; Zhang X; Karadkhelkar N; Zhou J; Ding K; Pan J; Yoganathan S; Yang DH; Chen ZS
Cancer Lett; 2020 Mar; 472():132-141. PubMed ID: 31837444
[TBL] [Abstract][Full Text] [Related]
68. Inducible SHP-2 activation confers resistance to imatinib in drug-tolerant chronic myeloid leukemia cells.
Li X; Pang J; Xue W; Wang Y; Tian T; Elgehama A; Wu X; Wu X; Sun Y; Qiu H; Shen Y; Xu Q
Toxicol Appl Pharmacol; 2018 Dec; 360():249-256. PubMed ID: 30290167
[TBL] [Abstract][Full Text] [Related]
69. Upregulation of miR-181c inhibits chemoresistance by targeting ST8SIA4 in chronic myelocytic leukemia.
Zhao L; Li Y; Song X; Zhou H; Li N; Miao Y; Jia L
Oncotarget; 2016 Sep; 7(37):60074-60086. PubMed ID: 27527856
[TBL] [Abstract][Full Text] [Related]
70. Kinesin spindle protein inhibitor SB743921 induces mitotic arrest and apoptosis and overcomes imatinib resistance of chronic myeloid leukemia cells.
Yin Y; Sun H; Xu J; Xiao F; Wang H; Yang Y; Ren H; Wu CT; Gao C; Wang L
Leuk Lymphoma; 2015 Jun; 56(6):1813-20. PubMed ID: 25146433
[TBL] [Abstract][Full Text] [Related]
71. The antiproliferation effect of berbamine on k562 resistant cells by inhibiting NF-kappaB pathway.
Wei YL; Liang Y; Xu L; Zhao XY
Anat Rec (Hoboken); 2009 Jul; 292(7):945-50. PubMed ID: 19548306
[TBL] [Abstract][Full Text] [Related]
72. PD166326, a novel tyrosine kinase inhibitor, has greater antileukemic activity than imatinib mesylate in a murine model of chronic myeloid leukemia.
Wolff NC; Veach DR; Tong WP; Bornmann WG; Clarkson B; Ilaria RL
Blood; 2005 May; 105(10):3995-4003. PubMed ID: 15657179
[TBL] [Abstract][Full Text] [Related]
73. Hsp90 inhibitor, BIIB021, induces apoptosis and autophagy by regulating mTOR-Ulk1 pathway in imatinib-sensitive and -resistant chronic myeloid leukemia cells.
He W; Ye X; Huang X; Lel W; You L; Wang L; Chen X; Qian W
Int J Oncol; 2016 Apr; 48(4):1710-20. PubMed ID: 26892093
[TBL] [Abstract][Full Text] [Related]
74. Novel Acylguanidine Derivatives Targeting Smoothened Induce Antiproliferative and Pro-Apoptotic Effects in Chronic Myeloid Leukemia Cells.
Chiarenza A; Manetti F; Petricci E; Ruat M; Naldini A; Taddei M; Carraro F
PLoS One; 2016; 11(3):e0149919. PubMed ID: 26934052
[TBL] [Abstract][Full Text] [Related]
75. Suppression of survivin induced by a BCR-ABL/JAK2/STAT3 pathway sensitizes imatinib-resistant CML cells to different cytotoxic drugs.
Stella S; Tirrò E; Conte E; Stagno F; Di Raimondo F; Manzella L; Vigneri P
Mol Cancer Ther; 2013 Jun; 12(6):1085-98. PubMed ID: 23536723
[TBL] [Abstract][Full Text] [Related]
76. Downregulation of topoisomerase 1 and 2 with acriflavine sensitizes bladder cancer cells to cisplatin-based chemotherapy.
Zargar P; Koochakkhani S; Hassanzadeh M; Ashouri Taziani Y; Nasrollahi H; Eftekhar E
Mol Biol Rep; 2022 Apr; 49(4):2755-2763. PubMed ID: 35088375
[TBL] [Abstract][Full Text] [Related]
77. Aberrantly low STAT3 and STAT5 responses are associated with poor outcome and an inflammatory gene expression signature in pediatric acute myeloid leukemia.
Narayanan P; Man TK; Gerbing RB; Ries R; Stevens AM; Wang YC; Long X; Gamis AS; Cooper T; Meshinchi S; Alonzo TA; Redell MS
Clin Transl Oncol; 2021 Oct; 23(10):2141-2154. PubMed ID: 33948920
[TBL] [Abstract][Full Text] [Related]
78. Synergism of a novel MCL‑1 downregulator, acriflavine, with navitoclax (ABT‑263) in triple‑negative breast cancer, lung adenocarcinoma and glioblastoma multiforme.
Lee A; Jin HO; Masudul Haque M; Kim HY; Jung H; Park JH; Kim I; Song JY; Yoon HK; Kim HK; Han J; Park IC; Kim KS; Park SG
Int J Oncol; 2022 Jan; 60(1):. PubMed ID: 34913076
[TBL] [Abstract][Full Text] [Related]
79. Acriflavine-loaded solid lipid nanoparticles: preparation, physicochemical characterization, and anti-proliferative properties.
Vandghanooni S; Rasoulian F; Eskandani M; Akbari Nakhjavani S; Eskandani M
Pharm Dev Technol; 2021 Nov; 26(9):934-942. PubMed ID: 34338582
[TBL] [Abstract][Full Text] [Related]
80. SPAG5: An Emerging Oncogene.
He J; Green AR; Li Y; Chan SYT; Liu DX
Trends Cancer; 2020 Jul; 6(7):543-547. PubMed ID: 32291236
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
